Obstructive sleep apnea: a major risk factor for COVID-19 encephalopathy?

Humans COVID-19 / complications Sleep Apnea, Obstructive / complications Brain Diseases / diagnostic imaging Risk Factors Polysomnography
COVID-19 encephalopathy Obstructive sleep apnea SARS-CoV-2

Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
27 Sep 2023
Historique:
received: 04 04 2023
accepted: 15 09 2023
medline: 20 11 2023
pubmed: 27 9 2023
entrez: 26 9 2023
Statut: epublish

Résumé

This study evaluates the impact of high risk of obstructive sleep apnea (OSA) on coronavirus disease 2019 (COVID-19) acute encephalopathy (AE). Between 3/1/2020 and 11/1/2021, 97 consecutive patients were evaluated at the Geneva University Hospitals with a neurological diagnosis of COVID-19 AE. They were divided in two groups depending on the presence or absence of high risk for OSA based on the modified NOSAS score (mNOSAS, respectively ≥ 8 and < 8). We compared patients' characteristics (clinical, biological, brain MRI, EEG, pulmonary CT). The severity of COVID-19 AE relied on the RASS and CAM scores. Most COVID-19 AE patients presented with a high mNOSAS, suggesting high risk of OSA (> 80%). Patients with a high mNOSAS had a more severe form of COVID-19 AE (84.8% versus 27.8%), longer mean duration of COVID-19 AE (27.9 versus 16.9 days), higher mRS at discharge (≥ 3 in 58.2% versus 16.7%), and increased prevalence of brain vessels enhancement (98.1% versus 20.0%). High risk of OSA was associated with a 14 fold increased risk of developing a severe COVID-19 AE (OR = 14.52). These observations suggest an association between high risk of OSA and COVID-19 AE severity. High risk of OSA could be a predisposing factor leading to severe COVID-19 AE and consecutive long-term sequalae.

Sections du résumé

BACKGROUND BACKGROUND
This study evaluates the impact of high risk of obstructive sleep apnea (OSA) on coronavirus disease 2019 (COVID-19) acute encephalopathy (AE).
METHODS METHODS
Between 3/1/2020 and 11/1/2021, 97 consecutive patients were evaluated at the Geneva University Hospitals with a neurological diagnosis of COVID-19 AE. They were divided in two groups depending on the presence or absence of high risk for OSA based on the modified NOSAS score (mNOSAS, respectively ≥ 8 and < 8). We compared patients' characteristics (clinical, biological, brain MRI, EEG, pulmonary CT). The severity of COVID-19 AE relied on the RASS and CAM scores.
RESULTS RESULTS
Most COVID-19 AE patients presented with a high mNOSAS, suggesting high risk of OSA (> 80%). Patients with a high mNOSAS had a more severe form of COVID-19 AE (84.8% versus 27.8%), longer mean duration of COVID-19 AE (27.9 versus 16.9 days), higher mRS at discharge (≥ 3 in 58.2% versus 16.7%), and increased prevalence of brain vessels enhancement (98.1% versus 20.0%). High risk of OSA was associated with a 14 fold increased risk of developing a severe COVID-19 AE (OR = 14.52).
DISCUSSION CONCLUSIONS
These observations suggest an association between high risk of OSA and COVID-19 AE severity. High risk of OSA could be a predisposing factor leading to severe COVID-19 AE and consecutive long-term sequalae.

Identifiants

DOI: 10.1186/s12883-023-03393-2 PMID: 37752429 PMC: PMC10523731
pubmed: 37752429
doi: 10.1186/s12883-023-03393-2
pii: 10.1186/s12883-023-03393-2
pmc: PMC10523731
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

340

Informations de copyright

© 2023. The Author(s).

Références

J Crit Care. 2020 Apr;56:120-124
pubmed: 31896445
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Sleep. 2014 Nov 01;37(11):1825-32
pubmed: 25364078
Clin Neuroradiol. 2022 Mar;32(1):287-293
pubmed: 33770199
Eur Respir J. 2021 Oct 7;58(4):
pubmed: 33737411
Am J Respir Crit Care Med. 2020 Nov 15;202(10):1462-1464
pubmed: 32946275
Crit Care. 2020 Aug 8;24(1):491
pubmed: 32771053
Intensive Care Med. 2020 May;46(5):1020-1022
pubmed: 32055887
Stroke. 2005 Apr;36(4):777-81
pubmed: 15718510
Sleep Med Rev. 2021 Feb;55:101382
pubmed: 32980614
Am J Respir Crit Care Med. 2017 Jul 15;196(2):200-207
pubmed: 27973930
J Med Virol. 2021 Jul;93(7):4374-4381
pubmed: 33782993
Eur Respir J. 2022 Mar 17;59(3):
pubmed: 34413154
Neurology. 2020 Sep 22;95(12):543-546
pubmed: 32680950
Sleep Med Rev. 2020 Aug;52:101309
pubmed: 32234658
Radiology. 2018 Jan;286(1):12-28
pubmed: 29261469
Sleep Breath. 2021 Jun;25(2):1155-1157
pubmed: 32989673
Brain. 2020 Oct 1;143(10):3089-3103
pubmed: 32645151
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Chest. 2013 Sep;144(3):896-902
pubmed: 23702567
Am J Respir Crit Care Med. 2017 May 1;195(9):1244-1252
pubmed: 28128967
Sleep Breath. 2021 Jun;25(2):849-860
pubmed: 33907966
J Med Virol. 2020 Nov;92(11):2272-2273
pubmed: 32530534
Lancet Respir Med. 2019 Aug;7(8):687-698
pubmed: 31300334
Chest. 2020 Sep;158(3):1198-1207
pubmed: 32247716
Anesthesiology. 2012 Apr;116(4):788-96
pubmed: 22337162
Chest. 2022 Jun;161(6):1657-1665
pubmed: 35176275
Ann Neurol. 2020 Jul;88(1):1-11
pubmed: 32506549
Chest. 2021 Aug;160(2):e161-e164
pubmed: 33930384
Respiration. 2021;100(10):1016-1026
pubmed: 34333497
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Nat Rev Dis Primers. 2015 Jun 25;1:15015
pubmed: 27188535
Lancet Respir Med. 2016 Sep;4(9):742-748
pubmed: 27321086

Auteurs

Gautier Breville (G)

Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. gautier.breville@pennmedicine.upenn.edu.
Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland. gautier.breville@pennmedicine.upenn.edu.

François Herrmann (F)

Department of Rehabilitation and Geriatrics, Division of Geriatrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

Dan Adler (D)

Division of Pneumology, La Tour Hospital, Geneva, Switzerland.

Christine Deffert (C)

Laboratory of Biological Fluids, Laboratory Medicine Division, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland.
Laboratory Medicine Division, Department of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Giulia Bommarito (G)

Leenaards Memory Center, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Patrick Stancu (P)

Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.

Alice Accorroni (A)

Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.

Marjolaine Uginet (M)

Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.

Frederic Assal (F)

Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.

Renaud Tamisier (R)

Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, HP2, 38000, Grenoble, France.

Patrice H Lalive (PH)

Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Diagnostic Department, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland.

Jean-Louis Pepin (JL)

Division of Pneumology, La Tour Hospital, Geneva, Switzerland.
Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, HP2, 38000, Grenoble, France.

Karl-Olof Lövblad (KO)

Division of Neuroradiology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

Gilles Allali (G)

Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.
Leenaards Memory Center, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Department of Neurology, Division of Cognitive and Motor Aging, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Obstructive sleep apnea: a major risk factor...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Obstructive sleep apnea: a major risk factor...
questionsmedicales.fr › Maladies du système nerveux › Syndromes d'apnées du sommeil › Syndrome d'apnées obstructives du sommeil › Obstructive sleep apnea: a major risk factor...
questionsmedicales.fr › Maladies du système nerveux › Maladies du système nerveux central › Encéphalopathies › Obstructive sleep apnea: a major risk factor...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Obstructive sleep apnea: a major risk factor...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Monitorage physiologique › Polysomnographie › Obstructive sleep apnea: a major risk factor...